MRC1 and melanoma: Nivolumab plus relatlimab showed impressive activity as neoadjuvant therapy in a single-arm study in melanoma, with a major pathologic response rate of 63%11, and in MMR-deficient colon cancer, with a major pathologic response rate of 92%12.